In a phase 2b randomized placebo-controlled trial, semaglutide 2.4 mg OW significantly reduced abdominal visceral, subcutaneous, and total body fat in people with HIV-associated lipohypertrophy without diabetes [152] (Figs
H.AnsariA
Gross necropsy and histopathologic examination of animals receiving high-dose BPC-157 found no organ damage in liver, spleen, lung, kidney, brain, thymus, prostate, ovaries, or gastric wall
Nat Commun 14 , 3737 (2023)
This small molecule, known scientifically as 5-amino-1-methylquinolinium , works by blocking an enzyme called NNMT (nicotinamide N-methyltransferase), which plays a key role in fat storage
Overview over study participants